Your session is about to expire
← Back to Search
Monoclonal Antibodies
700mg Leronlimab for COVID-19
Phase 2
Waitlist Available
Research Sponsored by CytoDyn, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
- Diagnosed with COVID-19 by standard RT-PCR assay or equivalent testing within 5 days of screening
OR - Shock (defined by SBP < 90 mm Hg, or Diastolic BP < 60 mm Hg or requiring vasopressors)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28
Awards & highlights
Study Summary
This trial is testing an experimental drug to see if it can help people with severe or critical cases of COVID-19.
Eligible Conditions
- COVID-19
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 28
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
All-cause mortality at Day 28
Secondary outcome measures
All-cause mortality at Day 14
Change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14.
Change in clinical status of subject at Day 14 (on a 7 point ordinal scale)
+1 moreSide effects data
From 2021 Phase 2 trial • 86 Patients • NCT043436515%
C-reactive protein increased
5%
Urinary Tract Infection
2%
Acute kidney injury
2%
Dyspnoea
2%
Peripheral ischaemia
2%
Fatigue
2%
Death
2%
Liver Abcess
2%
Presyncope
2%
respiratory failure
2%
Arterial occlusive disease
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
700mg Leronlimab
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: 700mg LeronlimabExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Leronlimab (700mg)
2021
Completed Phase 2
~150
Find a Location
Who is running the clinical trial?
CytoDyn, Inc.Lead Sponsor
23 Previous Clinical Trials
2,164 Total Patients Enrolled
4 Trials studying COVID-19
1,070 Patients Enrolled for COVID-19
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger